Clinical Trials

 Inclusion Criteria:                                                                  

• Community acquired pneumonia: one of the following:
  • CXR or CT evidence of pulmonary infiltrate;
  • Clinical impression as documented by physician or advanced practice provider.
• Symptom duration not longer than 14 days.
• Age ≥18 years.
• Inpatient or Outpatient.

 Exclusion Criteria:

• Known prior coccidioidal illness (prior to onset of current illness):
  • Known prior coccidioidal history;
  • Known prior positive coccidioidal skin test;
  • Known prior coccidioidal serology in past.        
• Health-care associated pneumonia:
  • Hospitalization in an acute care hospital for ≥ 2 days within 90 days of current infection;
  • Residence in nursing home or long-term care facility;
  • Recent IV antibiotic therapy, chemotherapy or wound care ≤ 30 days prior to current infection, given for a pneumonia indication;
  • Attended a hemodialysis clinic within 30 days.
• Active COVID-19 infection (i.e., positive PCR or antigen test in the previous 4 months for which symptoms had yet to resolve.  Persistent symptoms (fever, cough, headache, chest pain, shortness of breath) that are unresolved are grounds for exclusion.
• No exclusions for underlying health problems other than the above. Patients with underlying immunosuppression will be enrolled only as a subset of total patients enrolled.  Acceptable underlying immunosuppression will be defined as the receipt of immunosuppressive medications (within ≤ 3 months) such as but not limited to systemic corticosteroids greater than or equal to an equivalent dose of prednisone 5 milligrams daily, calcineurin inhibitors (tacrolimus, etc.), mycophenolate mofetil, rapamycin, others.

Eligibility last updated 10/5/21. Questions regarding updates should be directed to the study team contact.